RT Journal Article
SR Electronic
T1 Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.07.20245241
DO 10.1101/2020.12.07.20245241
A1 Dugas, Martin
A1 Grote-Westrick, Tanja
A1 Merle, Uta
A1 Fontenay, Michaela
A1 Kremer, Andreas E.
A1 Hanses, Frank
A1 Vollenberg, Richard
A1 Lorentzen, Eva
A1 Tiwari-Heckler, Shilpa
A1 Duchemin, Jérôme
A1 Ellouze, Syrine
A1 Vetter, Marcel
A1 Fürst, Julia
A1 Schuster, Philipp
A1 Brix, Tobias
A1 Denkinger, Claudia M.
A1 Müller-Tidow, Carsten
A1 Schmidt, Hartmut
A1 Tepasse, Phil-Robin
A1 Kühn, Joachim
YR 2021
UL http://medrxiv.org/content/early/2021/01/07/2020.12.07.20245241.abstract
AB Most COVID-19 patients experience a mild disease; a minority suffers from critical disease.We report about a biomarker validation study regarding 296 patients with confirmed SARS-CoV-2 infections from four tertiary care referral centers in Germany and France.Patients with critical disease had significantly less anti-HCoV OC43 nucleocapsid protein antibodies compared to other COVID-19 patients (p=0.007). In multivariate analysis, OC43 negative inpatients had an increased risk of critical disease, higher than the risk by increased age or BMI, and lower than the risk by male sex. A risk stratification based on sex and OC43 serostatus was derived from this analysis.Our results indicate that prior infections with seasonal human coronaviruses can protect against a severe course of COVID-19. Anti-OC43 antibodies should be measured for COVID-19 inpatients and considered as part of the risk assessment. We expect individuals tested negative for anti-OC43 antibodies to particularly benefit from vaccination, especially with other risk factors prevailing.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00023322Funding StatementSupported by grants from BMBF (HiGHmed 01ZZ1802V, Use Case Infection Control; 01KI20152 RECOVER trial), Bavarian State Ministry for Sciences and Art (TP-10 and TP-11 to AEK), and National research network for University Medicine (NUM to AEK and MD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following ethics committees gave approval to this study: Muenster: AZ 2020-210-f-S (Ethik-Kommission der Aerztekammer Westfalen-Lippe und der Westfaelischen Wilhelms-Universitaet Muenster) Heidelberg: S-148/2020 (Ethikkommission der Medizinischen Fakultaet Heidelberg) Paris: AAA-2020-08023 (Comite d'ethique de la Recherche de l'universite Paris Descartes) Erlangen: 174_20B (Ethikkommission der Friedrich-Alexander-Universitaet Erlangen-Nuernberg) Regensburg: 20-1785-101 (Ethikkommission bei der Universitaet Regensburg) All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFor data protection reasons, patient-level data is not available.